


Sparsentan

Chemical Properties

CAS No. :	254740-64-2
Formula:	C32H40N4O5S
Molecular Weight:	592.75
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Sparsentan (DARA-a) is a first-in-class orally active and highly potent dual endothelin A and angiotensin II receptor antagonist (K _i of 9.3 and 0.8 nM, respectively)
Targets(IC50)	RAAS, Endothelin Receptor

Solubility Information

Solubility	DMSO: 260 mg/mL (438.63 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.37 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6871 mL	8.4353 mL	16.8705 mL
5 mM	0.3374 mL	1.6871 mL	3.3741 mL
10 mM	0.1687 mL	0.8435 mL	1.6871 mL
50 mM	0.0337 mL	0.1687 mL	0.3374 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Murugesan N, et al. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005 Jan 13;48(1): 171-9.

Komers R , Diva U , Inrig J K , et al. Study Design of the Phase 3 Sparsentan vs Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis (FSGS)[J]. Kidney International Reports, 2020, 5(4).

Komers R , Gipson D S , Nelson P , et al. Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)[J]. Kidney International Reports, 2017:654-664.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481